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1. Clinical Cytogenetics
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Cryptic terminal chromosomal rearrangements are known to cause hu-
man genetic diseases. They are mostly undetectable by conventional
chromosome analysis even of the highest resolution. Subtelomere
fluorescence in situ hybridisation (FISH) analysis has increasingly been
used as an adjunct to routine cytogenetic testing in order to detect
small rearrangements. Indications for this application are: 1) conspicu-
ous familial medical history, 2) ultrasound abnormalities in a previous
pregnancy, 3) late abortion/IUFT/still birth.
Here we present four couples with remarkable medical history. We
found in a mother, (case 1), with ultrasound abnormalities in two
fetuses, a 10q/11p subtelomeric cryptic reciprocal translocation
(crt). In the fifth abortion of a woman (case 2) we found a pater-
nally inherited unbalanced form of the 8q/11q translocation detected
by array-CGH. In case 3, a mother, who had a stillbirth at 28 weeks of
gestation, a crt 6q/8q was found. Furthermore, a 1q/16p crt was seen
in a man whose partner had recurrent abortions (case 4).
The clinical information including the family history of these patients
will be summarized and compared with the current literature.
We propose the use of subtelomere FISH as a reliable, rapid and eco-
nomical first approach to detect unbalanced terminal chromosomal
rearrangements, especially in absence of major chromosome rear-
rangements in routine diagnosis. Detailed analysis of the family
history helps to choose further methods of more diagnostic power.
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Chromosome abnormalities account for 50% of all spontaneous
miscarriages and are present in 0,5-1% of all newborn infants.
The present study was undertaken to investigate the different types of
structural chromosomal aberrations and their relative frequencies in a
group of patients with suspected genetic disorders in the Romanian
population, and to identify precisely the role of cytogenetic investigation
in confirming the diagnosis, thus allowing proper genetic counseling.
Material and Methods
We cytogenetically investigated a total of 927 patients using the G
banding technique for identifying and characterizing the chromo-
somes of lymphocytes.
Results
We identified a total of 121 chromosomal aberrations (13%), of which 83
were numerical abnormalities (8.9%) and 38 were structural abnormalities
(4.1%). Of the 38 structural abnormalities, 28 were autosomal chromosomal
abnormalities. Changes in chromosome structure encountered were: differ-
ent translocations-11 cases, deletions-7 cases, inversions-5 cases, 3 cases
chromosomal polymorphisms, and 2 cases of marker chromosomes.
Conclusions
Detection of structural chromosomal abnormalities is a key element
for both correct etiological diagnosis and genetic counseling. The
results are comparable to those of similar studies.
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Rothmund-Thomson syndrome (RTS) is a rare autosomal recessively
transmitted genodermatosis associated with congenital bone defects
and increased risk of osteosarcoma and skin cancer. RTS is caused by
homozygous or compound heterozygous RECQL4 mutations. RecQ
helicases are implicated in damaged DNA replication fork repair and
are assumed to play roles in the maintenance of genome stability.
Some previous cytogenetic studies described mosaic trisomy 8 in RTS
patients, an intriguing finding because RECQL4 is located on 8q24.3.
However, it is unknown if these findings point towards a causal associ-
ation because the functional implications would be difficult to explain.
To address this question, we performed a blinded, unbiased interphase
FISH screen for copy number changes of all chromosomes and M-FISH
karyotyped more than 200 metaphases from a RTS patient.
Our interphase FISH analysis provided no evidence for a general in-
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revealed a 2.7% translocation rate in our patient, representing a sig-
nificant and up to 5.7x increase compared to baseline frequencies in
healthy age matched controls from the literature.
We conclude that aneuploidy, and in particular mosaic trisomy 8 is not
an apparent pathogenic mechanism in the RTS patient we have analysed.
However, and in line with the proposed function of RECQL4 in DNA repli-
cation and genome surveillance, we found evidence that increased struc-
tural genome instability might be associated with the RTS phenotype.
2. Tumour Cytogenetics
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(MDS) is associated to a better outcome but it is also well described
as an age-related phenomenon. In this study we aimed to analyze
the prognostic impact of -Y in the context of the IPSS-R cytogenetic
classification, evaluate the clinical significance of the percentage of
metaphases with isolated -Y, and test whether finding -Y may predis-
pose to over-diagnose MDS in patients with borderline morpho-
logical features. We evaluated 3,581 male patients from the Spanish
MDS Registry with a diagnosis of MDS or chronic myelomonocytic
leukemia (CMML). -Y was identified in 177 patients (4.9%). Compared
with the 2,246 male patients with normal karyotype, -Y group
showed a reduced risk of leukemic transformation that did not trans-
late into a survival advantage. The overall survival and the risk of
leukemic transformation were not influenced by the percentage of
metaphases with -Y. The -Y group was not enriched in patients with
minor morphologic traits of dysplasia, suggesting that the better out-
come in the -Y group cannot be explained by enrichment in cases
misdiagnosed as MDS. In conclusion, our results support the current
recommendation of classifying patients with -Y within the very good
risk category of the IPSS-R for MDS and rule out a selection bias as a
possible explanation of this better outcome. An analysis of the mo-
lecular basis of MDS with isolated -Y would be of interest as it may
provide a biological basis of protection against progression to acute
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